Crossmark Global Holdings’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-15,190
| Closed | -$2.79M | – | 1449 |
|
|
2021
Q2 | $2.79M | Buy |
15,190
+293
| +2% | +$50.3K | 0.07% | 292 |
|
|
2021
Q1 | $2.28M | Sell |
14,897
-930
| -6% | -$144K | 0.06% | 335 |
|
|
2020
Q4 | $2.47M | Sell |
15,827
-1,438
| -8% | -$185K | 0.06% | 325 |
|
|
2020
Q3 | $1.98M | Sell |
17,265
-104
| -0.6% | -$11.2K | 0.06% | 346 |
|
|
2020
Q2 | $1.95M | Buy |
17,369
+590
| +4% | +$62.6K | 0.06% | 344 |
|
|
2020
Q1 | $1.51M | Buy |
16,779
+913
| +6% | +$89.6K | 0.05% | 357 |
|
|
2019
Q4 | $1.72M | Sell |
15,866
-369
| -2% | -$39.5K | 0.05% | 414 |
|
|
2019
Q3 | $1.59M | Sell |
16,235
-628
| -4% | -$70.8K | 0.05% | 425 |
|
|
2019
Q2 | $2.21M | Buy |
16,863
+548
| +3% | +$70.6K | 0.06% | 355 |
|
|
2019
Q1 | $2.21M | Sell |
16,315
-85
| -0.5% | -$10.6K | 0.06% | 350 |
|
|
2018
Q4 | $1.6M | Sell |
16,400
-1,208
| -7% | -$143K | 0.05% | 414 |
|
|
2018
Q3 | $2.45M | Sell |
17,608
-1,061
| -6% | -$133K | 0.06% | 349 |
|
|
2018
Q2 | $2.32M | Sell |
18,669
-634
| -3% | -$74.1K | 0.06% | 349 |
|
|
2018
Q1 | $2.15M | Sell |
19,303
-2,014
| -9% | -$241K | 0.06% | 389 |
|
|
2017
Q4 | $2.55M | Buy |
21,317
+1,396
| +7% | +$170K | 0.06% | 363 |
|
|
2017
Q3 | $2.79M | Buy |
+19,921
| New | +$2.71M | 0.07% | 328 |
|
|
2016
Q3 | $2.79M | Buy |
+19,921
| New | +$2.56M | 0.07% | 328 |
|
Other funds holding ALXN
BCI
NICM
TAIM
RG
CFO
MAM